# Constructive Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/constructive-biology

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.constructive.bio/
- Total disclosed funding: $74M
- Latest round: Series A (Mar 27, 2025)
- Investors on record: 8

## About

Based in the UK, Constructive Biology Limited is a biotechnology firm specializing in innovative solutions for programmable biomolecules and genome writing, addressing significant challenges in drug discovery and biomanufacturing.Constructive Biology Limited, founded in 2021, is headquartered in Cambridge, UK. The company focuses on developing advanced biotechnology solutions. Jason Chin is the founder, and Ola Wlodek serves as the CEO. Since its inception, the company has secured a total of GBP 58.00 mn across multiple funding rounds, with the most recent funding being a Grant of GBP 1.10 mn from Innovate UK on March 27, 2025. The firm has completed four deals to date.Constructive Biology Limited specializes in innovative biotechnology solutions, focusing on the synthesis of programmable biomolecules and whole genome writing. Their core offerings include the patented Syn61 strain, which allows for the expansion of the genetic code and the creation of highly specific biomolecules. This technology addresses challenges in drug discovery and biomanufacturing, enabling advancements in next-generation therapeutics, such as antibody drug conjugates, and industrial applications, including the development of phage-resistant strains. The company primarily serves the pharmaceutical and biotechnology sectors, targeting clients such as research institutions and companies engaged in drug development and biomanufacturing processes. Their products are marketed globally, emphasizing regions with robust biopharmaceutical industries, including North America and Europe.Constructive Biology Limited generates revenue through strategic partnerships and direct business arrangements with clients in the biotechnology and pharmaceutical sectors. The company engages in B2B transactions, where clients utilize its Syn61 strain and other proprietary technologies for their biomanufacturing needs. Revenue is derived from licensing agreements, collaborations for R&D initiatives, and supply contracts related to the provision of customizable biomolecules. The structure of these transactions includes upfront fees, milestone payments tied to development progress, and ongoing royalties based on product sales. Specific pricing details for their services and products are structured to reflect the value of the advanced technologies offered, although these details are proprietary to the company.Constructive Biology Limited plans to utilize the recent Grant funding to enhance its genome writing platform and synthetic biology capabilities, which will enable the development of scalable solutions for therapeutics, biomaterials, and sustainable manufacturing. The company is also exploring opportunities to expand into new markets, targeting specific regions known for their biopharmaceutical industries by 2026. Upcoming product launches include new programmable biomolecules designed to further assist clients in drug discovery and biomanufacturing processes.

## Funding rounds

- Series A, Mar 27, 2025 — Paladin Capital Group, +ND Capital, Ahren Innovation Capital, OMX Ventures, LongeVC, Fine Structure Ventures
- Series A, Sep 4, 2024, $59M — Paladin Capital Group, +ND Capital, Ahren Innovation Capital, OMX Ventures, Fine Structure Ventures
- Seed, May 13, 2022, $15M — Amadeus Capital Partners, Ahren Innovation Capital, OMX Ventures, General Inception

## Investors

- Amadeus Capital Partners (https://capitalatlas.ai/funds/amadeus-capital-partners) — Seed
- Ahren Innovation Capital (https://capitalatlas.ai/funds/ahren-innovation-capital) — Seed, Series A
- OMX Ventures (https://capitalatlas.ai/funds/omx-ventures) — Seed, Series A
- General Inception (https://capitalatlas.ai/funds/general-inception) — Seed
- Paladin Capital Group (https://capitalatlas.ai/funds/paladin-capital-group) — Series A
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series A
- Fine Structure Ventures (https://capitalatlas.ai/funds/fine-structure-ventures) — Series A
- LongeVC (https://capitalatlas.ai/funds/longevc) — Series A